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It is established that primary malignant melanomas (pMM) can be infiltrated by T-cell populations with
predominantly one T-cell clone. As pMM generally express multiple tumor-associated antigens (TAA), here we
used laser-capture microdissection (LCM) to isolate different tumor-infiltrating lymphocyte (TIL) clusters in
order to determine whether pMM are infiltrated only by one single clone or whether the TAA may attract
various T-cell populations. As T-cell receptor (TCR) clonality is a useful tool for the demonstration of specific T-
cell clones, we analyzed 56 pMM, three cutaneous melanoma metastases, and 15 pairs of pMM with a sentinel
lymph node (SLN) for clonal rearrangements of the (TCR) g chain gene. We detected the clonality of TCR g chain
gene in 25 of 56 pMM, and in 10 of 17 SLN studied. In four of the 15 pairs of primary tumor and SLN, we found
clonal TCR g in both the melanoma and the SLN, with two pairs harboring the identical clone. As we detected
different clones in pMM and the corresponding SLN, we subsequently performed LCM in 21 malignant
melanomas with multiple lymphocytic clusters for the presence of focal clonal T cells in different regions of the
melanoma. In seven melanomas, both clusters of TILs showed the same rearranged TCR g chain gene and in five
of the seven biopsies the clonal rearrangement occurred in different variable (V) regions of the TCR g chain
gene. These tumors showed infiltration by more than one clone. In 10 biopsies TCR clonality was restricted to
one cluster, while the second microdissected sample of the infiltrate was polyclonal. In conclusion, within one
primary malignant melanoma several T-cell clones with different rearrangements may occur. The balance
between these clones may decide on the progress of melanoma.
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INTRODUCTION
Primary malignant melanomas usually harbor various
amounts of tumor-infiltrating-lymphocytes (TIL). Tumor in-
filtration by TIL reflects a specific host response that results
from recognition of tumor-associated antigens either on
antigen-presenting cells or on the surface of the tumor cells
by T lymphocytes (Van der Bruggen et al., 2002).
The biological significance of the local T-cell-mediated
immune response is difficult to evaluate, as in malignant
melanoma the coexistence of either regression or progressive
and invasive tumor margins is frequently associated with a
dense lymphocytic infiltrate. Spontaneous regression is
defined as the partial or complete disappearance of tumor
masses without treatment (Cole, 1976) and is often histo-
logically characterized by a dense lymphocytic infiltrate of
T-helper cells (Lowes et al., 1997).
Previous reports revealed that tumor-infiltrating lympho-
cytes (TIL) in malignant melanoma are frequently of clonal
origin in both progressive and regressive parts of the identical
tumor (thor Straten et al., 1996) and in its metastases (thor
Straten et al., 1999). These findings raise the question of
whether one T-cell clone may exert both tumor-promoting
and tumor-inhibitory properties or whether tumors may
present several antigens and attract different T-cell popula-
tions. Two very recent studies found in the peripheral blood
and in melanoma metastases of patients vaccinated with
MAGE antigens several different T-cell clones recognizing
both the vaccinated antigen and other melanoma-associated
antigens (Germeau et al., 2005; Lurquin et al., 2005).
However, the clonal response against the primary malignant
melanoma, and not the secondary metastasis without
vaccination, remains unanswered.
Recent therapeutic trials in patients with metastatic
melanoma use in vitro highly tumor-specific T-cell clones
for adoptive transfer (Yee et al., 2000) with variable success.
As most of the vaccines used are major histocompatibility
complex (MHC) I restricted, the MHC expression of the tumor
was analyzed by performing immunohistochemistry with
antibodies against MHC I and MHC II. We further character-
ized the TIL by staining for CD4 and CD8 to determine the
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amount of cytotoxic CD8-positive lymphocytes needing
MHC I expression for tumor detection or MHC-II-dependent
CD4-positive T-helper cells.
Moreover, in malignant melanomas, antigen presentation
occurs either by direct recognition of the tumor cells by
cytotoxic T lymphocytes or by cross-presentation of tumor-
antigens via antigen-presenting cells, which can activate both
CD8- as well as CD4-positive TIL.
Determination of T-cell receptor (TCR) clonality is a tool
for the characterization of cutaneous lymphocytic infiltrates
(Holm et al., 2002). A new technical approach for the
detection of clonality is the usage of laser-capture micro-
dissection (LCM). This technique allows isolating small
clusters of cutaneous lymphocytic infiltrates. In a previous
study using LCM to evaluate clonality in cutaneous T-cell
lymphoma, we could demonstrate a superior sensitivity with
equal specificity when combined with analysis of TCR g
chain gene rearrangement of the entire block (Yazdi et al.,
2003). This superior sensitivity of the LCM method allows us
to detect several smaller clones instead of one dominant
clone found by conventional clonality analysis.
In the present study, we used LCM to characterize various
parts of the peritumoral infiltrate for TCR g chain gene
rearrangement in a large number of primary malignant
melanomas and sentinel lymph node (SLN) biopsies. In
sections showing a large amount of TIL forming distinct
clusters, we separately analyzed microdissected lymphocytic
infiltrates from several parts of the identical tumor for their
TCR g chain gene rearrangements and found that one single
melanoma can be infiltrated by more than one T-cell clone.
RESULTS
TCR c rearrangement in DNA extracted from total tumor
sections
DNA extracted from paraffin blocks of a total of 56 primary
malignant melanomas and three melanoma metastases was
analyzed for rearrangement of the TCR g chain gene. A clonal
TCR g chain gene rearrangement could be detected in 25 of
56 (45%) malignant melanomas and in one of three (33%)
melanoma metastases screened (Table 1).
In 15 patients, we analyzed the primary tumor and the
corresponding sentinel node. In four of the 15 patients, we
found TCR g chain gene rearrangement in both the melanoma
and the lymph node. In order to assure clonality, we
sequenced DNA in two of the four pairs of lymph nodes
and primary malignant melanomas. The data confirmed that
the clones were identical. One single T-cell clone was found
in two of the 15 primary melanomas, while the other
melanomas showed either multiple clones or polyclonal
infiltrates. In contrast, four of the 17 SLNs harbored a clearly
predominant T-cell clone (Table 2).
LCM reveals TCR heterogeneity at various sites of the infiltrate
As we found different T-cell clones in primary malignant
melanomas and their corresponding SLNs, and as melanomas
express more than one tumor-associated antigen (TAA), we
speculated that it is unlikely that TIL are composed by only
one single T-cell clone. We therefore performed LCM of two
Table 1. TCR c gene rearrangement examining the
entire lesion (conventional DNA extraction)
TNM Clark Breslow Clonality
Tis MM in situ Polyclonal
Tis MM in situ Polyclonal
T1 III 0.44 mm Vg2
T1 II 0.2 mm Vg2; Vg9; Vg11
T1 III 0.6 mm Vg9
T1 III 0.5 mm Vg2
T1 II 0.3 mm Vg2; Vg11
T1 II 0.3 mm Vg9; Vg10
T1 III 0.32 mm Vg9
T1 III 0.25 mm Vg2; Vg9
T1 II 0.24 mm Polyclonal
T1 II 0.5 mm Polyclonal
T1 III 0.42 mm Polyclonal
T1 III 0.56 mm Polyclonal
T1 III 0.4 mm Polyclonal
T1 III 0.56 mm Polyclonal
T1 III 0.36 mm Polyclonal
T1 III 0.36 mm Polyclonal
T1 III 0.4 mm Polyclonal
T1 III 0.5 mm Polyclonal
T1 III 0.5 mm Polyclonal
T1 II 0.6 mm Vg2
T1 II 0.18 mm Polyclonal
T1 III 0.23 mm Polyclonal
T2 III 1.3 mm Vg2
T2 IV 1.4 mm Polyclonal
T2 III 0.8 mm Polyclonal
T2 III 1.3 mm Polyclonal
T2 III 0.85 mm Vg2
T2 III 1.2 mm Polyclonal
T3 III 1.8 mm Vg11
T3 IV 2.7 mm Polyclonal
T3 III 1.8 mm Vg11;Vg9
T3 III 1.8 mm Vg9
T3 IV 1.74 mm Vg11
T3 IV 2.1 mm Vg2; Vg9
T3 IV 1.6 mm Vg2; Vg11
T3 III 3.7 mm Vg11
T3 III 3.7 mm Polyclonal
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sites of the peri- or intratumoral infiltrate and compared TCR
g chain gene rearrangement in 21 primary malignant
melanomas. These melanomas showed histologically at least
two distant areas of patchy lymphocytic infiltrates of
approximately 500–2,000 lymphocytes each. We found
TCR clonality in at least one site in 17 of the infiltrates. In
two out of the 17 infiltrates, two LCM sites revealed identical
TCR g chain gene rearrangement, while in 15 of the 17
infiltrates TCR g chain gene rearrangement was different
between the two LCM sites. Five of the 17 infiltrates showed
in each site a different clone and the other 10 had a
monoclonal infiltrate at one site and a predominantly
polyclonal infiltrate at the other site under the conditions
studied, meaning that no T-cell population exceeded 1% of
the entire TIL population.
As cytotoxic (CD8þ ) lymphocytes either need antigen-
presenting cells or HLA class I antigen expression, the HLA
status of the melanomas with dense lymphocytic infiltrates
was examined. In malignant melanoma, the antigen pre-
sentation can occur either by direct recognition of the tumor
cells by cytotoxic T lymphocytes or by crosspresentation of
tumor antigens via antigen-presenting cells, which can
activate both CD8- as well as CD4-positive TIL. Therefore,
additionally, the CD4/CD8 ratio of the TIL was determined
using immunohistochemistry. As shown in Table 3, no
correlation could be drawn between HLA expression and
the amount of CD4- or CD8-labelled T lymphocytes and TCR
g gene rearrangement.
DISCUSSION
Tumors, especially melanomas, can evoke immune responses
that include the activation of TAA-specific T cells (Romero
et al., 1998). TAA-specific T cells have been shown to
interfere even with the growth of established tumors in the
mouse (Greenberg, 1991; Egeter et al., 2000) and in humans
(Yee et al., 2000; Dudley et al., 2002). On the other side,
tumor-specific TIL do not exclusively exert protective
responses. Under still poorly defined conditions, tumor-
specific immune responses may also facilitate tumor growth.
Both regression and progression occur frequently simulta-
neously within one single melanoma. In order to elucidate
the underlying mechanisms, we started by analyzing the
heterogeneity of TIL within the lymphocytic infiltrate
surrounding primary melanomas. As functional heterogeneity
is difficult to determine in terms of DNA analysis, here we
looked for differences in TCR g chain gene rearrangement at
different sites of the infiltrate using LCM. In agreement with
published data, we found TCR g chain gene rearrangements
in 45% of primary malignant melanomas and in 59% of the
tumor-draining SLNs. Interestingly, we could detect clonality
in SLNs, the place where immune responses are triggered. In
order to assure clonality, we sequenced DNA in two of the
four pairs of lymph nodes and primary malignant melanomas.
The data confirmed that the clones were identical. One
explanation for this fact might be that a dominant T-cell clone
is attracted by antigen-expressing melanoma cells or antigen-
presenting cells and therefore showing a local expansion of a
dominant clone.
The distribution of the TCR g chain gene rearrangements at
distinct areas could previously not be performed with DNA
extracted from paraffin blocks. In studies published until
now, the samples always resulted from the entire block. Thus,
no statement can be given on locally expanded clones or the
distribution of clonal T-cell lymphocytes. To determine
whether TCR rearrangement is a focal event, we used an
LCM-assisted approach. Aggregates of TIL from two different
regions of one primary malignant melanoma were micro-
dissected and separately analyzed for TCR g chain gene
rearrangement.
Table 2. T-cell receptor c clonality of primary
malignant melanoma with sentinel lymph node
TNM Diagnosis Clonality
T1 III; 0.6 mm Vg9
LN w/o MM Polyclonal
T3 III; 1.8 mm Vg9
LN w/o MM Polyclonal
T3 III; 1.5 mm Polyclonal
LN w/o MM Vg9
T3 III; 1.7 mm Vg9; Vg11
LN w/o MM Vg9.
T3 IV; 1.8 mm Vg9
LN w/o MM Vg10
T3 III; 1.7 mm Vg10
LN w/o MM Vg2
T2 III; 1.4 mm Polyclonal
LN w/o MM Vg2; Vg11
T2 III–IV; 1.3 mm Vg9; Vg10
LN w/o MM Vg2
LN w/o MM Vg2; Vg9
T4 IV; 5.6 mm Polyclonal
LN with MM Vg2
LN w/o MM Vg11
T2 III; 1.1 mm Polyclonal
LN w/o MM Vg2
T2 III; 1.0 mm Polyclonal
LN with MM Polyclonal
T2 III; 1.2 mm Polyclonal
LN with MM Polyclonal
T2 IV; 1.4 mm Polyclonal
LN w/o MM Polyclonal
T3 IV; 1.6 mm Polyclonal
LN w/o MM Polyclonal
T1 III; 0.54 mm Polyclonal
LN w/o MM Polyclonal
LN with MM: sentinel lymph node with melanoma cells; LN w/o MM:
sentinel lymph node without melanoma cells.
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Comparing the two lymphocyte clusters, we detected a
rearrangement of the identical variable (V) region in only two
of the 21 tumors screened, with one tumor showing two
different clones in one of the microdissected TIL. It is
speculated that melanomas that harbor one single T-cell
clone have a favorable outcome and a tendency for
spontaneous regression (Ferradini et al., 1993). Yet, other
groups detected clonality in both regressive and progressive
regions of primary malignant melanomas (Salvi et al., 1995;
thor Straten et al., 1996). Histologically, there was no
regression at any site and no substitution of tumor nests by
fibrous tissue.
Five melanomas had clonal TCR g chain gene rearrange-
ments in two TIL clusters, but with various V regions
rearranged, suggesting that TIL recognize more than one
TAA in most tumors. These results are in line with a casuistic
report by thor Straten et al. (1999), who found high numbers
of locally expanded clonotypes in malignant melanoma
metastases from two patients. Yet, thor Straten et al. (1999)
used antibodies against specific TCR Vb, a clustering of
various Vb families, in a metastasis. Even though this analysis
does not allow to study clonal rearrangement, it suggests
enrichment of various clones in melanoma metastasis.
Surprisingly, half of the melanomas (10 of 21) showed
clonality in one TIL and a polyclonal infiltrate in the other. At
the first glance, this focal distribution of a clonal T-cell subset
depends neither on the thickness of the tumor nor on the
presence of regression, as the TIL clusters were not
microdissected from regressive regions.
Comparing the new LCM approach with clonality analysis
of the entire section (Table 3), 45% of the melanomas
screened carry one dominant clone detectable by conven-
tional TCR g chain rearrangement studies, while the new
method enables us to detect additional focal clones.
Interestingly, often the dominant clone was not found on
LCM, as the dominant clone in some tumors does not have to
be localized in the microdissected patchy infiltrates, but is
rather situated in the sparse infiltrate localized in the upper
papillary dermis.
In summary, our data show that TCR g chain gene
rearrangements are common in malignant melanoma. A
clonal gene rearrangement could be detected in 45% of the
56 melanomas screened. The presence of clonal TIL is a focal
event in most of the tumors analyzed, as we found different
clones in various regions of the same primary malignant
melanoma using LCM. Our results shed new light on the
Table 3. Results of the rearrangement studies from two different microdissected clusters of tumor-infiltrating
lymphocytes (LCM 1 and LCM 2) compared to the entire lesion and HLA expression of the lesion (HLA-A2
expression was graded by a homogenous expression (475%), a heterogenous expression (25–75%) or negative
expression of the melanoma cells)
TNM Clark Breslow Entire lesion LCM 1 LCM 2 CD4/CD8 HLA-A2
HLA-DP/DQ/
DR
Tis MM in situ Polyclonal Polyclonal Polyclonal CD84CD4 o25% Negative
Tis MM in situ Polyclonal Vg10 Polyclonal CD44CD8 75–100% Negative
T1 III 0.6 mm Vg9 Vg9 Polyclonal CD84CD4 25–75% Positive
T1 III 0.46 mm Vg2 Vg9 Polyclonal CD44CD8 o25% Negative
T1 III 0.7 mm Polyclonal Vg11 Vg2 CD4=CD8 25–75% Negative
T1 III 0.62 mm Vg10 Vg2 Vg10 CD4=CD8 75–100% Negative
T1 III 0.3 mm Polyclonal Polyclonal Polyclonal CD4=CD8 o25% Negative
T1 III 0.25 mm Vg2, Vg9 Vg10 Polyclonal CD4=CD8 25–75% Negative
T2 III 0.85 mm Vg2 Vg2 Vg9 CD4=CD8 75–100% Positive
T2 IV 0.8 mm Vg2 Vg9 Vg9 CD4=CD8 75–100% Negative
T3 IV 1.74 mm Vg11 Vg2 Vg9 CD84CD4 o25% Negative
T3 IV 3.3 mm Vg2, Vg11 Vg10 Vg10, Vg11 CD44CD8 o25% Positive
T3 IV 2.1 mm Vg2, Vg9 Vg11 Vg2, Vg9 CD4=CD8 75–100% Negative
T3 III 1.7 mm Vg9, Vg11 Polyclonal Vg10 CD84CD4 25–75% Negative
T3 IV 1.8 mm Vg9 Polyclonal Polyclonal CD4=CD8 75–100% Negative
T3 III 1.7 mm Vg10 Polyclonal Vg2 CD84CD4 25–75% Negative
T3 III 1.8 mm Vg9 Polyclonal Vg9 CD4=CD8 o25% Negative
T3 III 1.8 mm Vg9, Vg11 Vg11 Polyclonal NA NA NA
T3 IV 1.6 mm Vg2, Vg11 Polyclonal Polyclonal CD84CD4 25–75% Negative
T3 IV 2.2 mm Polyclonal Polyclonal Vg11 CD4=CD8 o25% Positive
T3 IV 2.9 mm Polyclonal Vg11 Polyclonal NA NA NA
NA, no melanoma left on the paraffin block.
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paradox of large lymphocytic infiltrates in progressive and
regressive areas of one single malignant melanoma (thor
Straten et al., 2000). As we previously showed that different
T-cell populations have different effects on tumor growth
(Egeter et al., 2000; Mocikat et al., 2003), the data here
suggest that different types of TIL may either inhibit or
promote melanoma growth in different areas of the same
tumor.
MATERIALS AND METHODS
Study cases and design
A total of 95 formalin-fixed and paraffin-embedded biopsies were
included in the study (Table 1). Samples included 56 primary
cutaneous malignant melanomas and three melanoma metastases. In
all, 15 pairs of a primary malignant melanoma with a SLN were
screened. Altogether, 14 lymph nodes did not contain any tumor
cells and three lymph nodes showed malignant melanoma cells (two
melanomas had two SLNs excised) (Table 2). Samples were
collected from the Dermatohistopathology Section of the Depart-
ment of Dermatology, Ludwig-Maximilians-University Munich, and
diagnosed by two dermatopathologists. Diagnoses were made
according to standard dermatohistological practice.
Immunohistochemistry
Expression of CD4, CD8, MHC I (HLA-A2), and MHC II (HLA-DP,
DQ, DR) was determined by immunohistochemistry. Briefly, 4-mm
sections were placed on coated glass slides, pretreated in 1 mM
EDTA (HLA-A2, CD4) or 10 mM citrate buffer (CD8) at 1001C for
5 minutes and incubated with monoclonal antibodies CD4 (Novo-
castra, UK), CD8 (Dako, Denmark), 0397HA and 0791HA (One
Lambda, Canoga Park, CA) (1:100), and HLA-DP, DQ, DR (Dako,
Denmark) (1:100), using the alkaline phosphatase anti-alkaline
phosphatase method (Dako, Denmark). HLA-A2 expression was
graded by a homogenous expression (475%), a heterogenous
expression (25–75%), or negative expression of the melanoma cells
(Anastassiou et al., 2003).
DNA extraction from paraffin-embedded tissue
SLN were divided into four sections. For DNA extraction in
metastatic SLN, we extracted DNA from sections carrying melanoma
cells, while in tumor-free SLNs DNA was extracted from central
sections.
For DNA extraction from formalin-fixed, paraffin-embedded
tissue, we used a modified version of the method described by
Shibata (Shibata et al., 1988; Graf et al., 1996). Briefly, 15–20 tissue
sections, each 10 mm thick, were cut, deparaffinized with xylene,
and washed with 100% ethanol. The samples were digested for 2
days with digestion buffer and proteinase K at 371C. DNA was
extracted using phenol/chloroform, followed by sodium-acetate
precipitation at 201C overnight. After being washed with 70%
ethanol, the DNA pellet was diluted in sterile water.
LCM and DNA extraction from captured cells
From 21 malignant melanoma specimens from 21 patients with a
prominent lymphocytic infiltrate (Table 3), one 10-mm-thick tissue
section was cut from the paraffin-embedded tissue block and stained
using hematoxylin. Two lymphocytic infiltrates (approximately
500–2000 cells each) from various regions of the section, which
were not adjacent to each other, were microdissected (Figure 1) with
a PixCell II Laser Capture Microdissection System (Arcturus
Engineering Inc., Mountain View, CA). The captured cells were
immediately transferred to proteinase K-enriched digestion buffer
(0.1 M Tris–HCl, 0.5 mM EDTA, 0.5% Tween 20). After an incubation
period of 5–12 hours at 481C, proteinase K was inactivated at 951C
for 10 minutes.
Presence of a sufficient amount of DNA was assured by
amplifying a fragment of the b-globin gene (primers PCO3/KM38)
as an internal control (Saiki et al., 1985).
PCR assessment of the TCR c gene
To theoretically cover all potential TCR g-chain gene rearrange-
ments, we used a parallel PCR approach with consensus primers
(Schuhmann et al., 1999), combining one of the four variable region
family primers (Vg1–8, Vg9, Vg10, and Vg11) with a mixture of four
joining primers (Jg2, Jgp, Jgp1, and Jgp2). Gene segments Vg1–Vg8
were covered by the consensus primer Vg2 (Graf et al., 1996). Each
DNA sample underwent four PCR reactions, one for each of the four
variable region families of the TCR g-chain gene. The T-cell line
Jurkat was used as a positive control for the Vg2 and Vg11 primers.
The T-cell line HSB2 was used for a positive control for Vg9 and
Vg10 primers.
The PCR conditions for DNA extracted by conventional methods
and for DNA isolated from LCM were identical, except for the size of
the reaction. A 50-ml reaction with only 2-ml DNA input was used for
analysis of DNA extracted from 15–20 10-mm-thick tissue sections. A
30-ml reaction was used with a DNA input of 3 ml for analysis of cells
obtained by LCM. After initial heating at 941C for 7 minutes, 45
cycles of PCR were carried out (941C denaturation for 30 seconds,
annealing 601C for 30 seconds, and extension at 721C for
30 seconds), followed by a 7-minute extension at 721C.
Figure 1. Histology of microdissected lymphocytes in primary malignant
melanoma. Primary malignant melanoma with clustered TIL and dissected
clusters of lymphocytes.
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The amplified products were run on 6% polyacrylamide gels,
stained with ethidium bromide, and visualized under ultraviolet
light. Contamination was avoided by strict technical methods. The
unmounted hematoxylin-stained 10 mm sides were prepared using
fresh and clean reagents. DNA extraction, PCR set-up steps, and the
processing of PCR products were performed in different rooms. New
gloves were used for each sample. Additionally, in all experiments,
negative controls were carried out through all steps with test
samples.
Sequencing
The two pairs of primary malignant melanoma and SLN, which
showed a TCR g chain gene rearrangement of the same V region,
were subjected to DNA sequencing to determine whether the two
clones were identical.
Four separate PCR reactions using the V primer with each J
primer (Jg2, Jgp, Jgp1, and Jgp2) were set up to explore which joining
primer is used. An aliquot of the PCR products was run on a 6%
polyacrylamide gel. The PCR reaction showing a monoclonal band
on the gel was subjected to direct sequencing using the ABI Prism
Dye Terminator cycle sequencing ready reaction kit (Applied
Biosystems) according to the manufacturer’s guidelines, using an
ABI 373A DNA sequencer (Applied Biosystems).
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